TissGeneSummary for PRSS50 |
Gene summary |
Basic gene information | Gene symbol | PRSS50 |
Gene name | protease, serine, 50 | |
Synonyms | CT20|TSP50 | |
Cytomap | UCSC genome browser: 3p21.31 | |
Type of gene | protein-coding | |
RefGenes | NM_013270.4, | |
Description | cancer/testis antigen 20probable threonine protease PRSS50serine protease 50testes specific protease 50testes-specific protease 50testis-specific protease-like protein 50 | |
Modification date | 20141207 | |
dbXrefs | MIM : 607950 | |
HGNC : HGNC | ||
Ensembl : ENSG00000206549 | ||
HPRD : 06405 | ||
Protein | UniProt: go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_PRSS50 | |
BioGPS: 29122 | ||
Pathway | NCI Pathway Interaction Database: PRSS50 | |
KEGG: PRSS50 | ||
REACTOME: PRSS50 | ||
Pathway Commons: PRSS50 | ||
Context | iHOP: PRSS50 | |
ligand binding site mutation search in PubMed: PRSS50 | ||
UCL Cancer Institute: PRSS50 | ||
Assigned class in TissGDB* | B | |
Included tissue-specific gene expression resources | ||
Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Testis | |
Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | TGCT | |
Reference showing the relevant tissue of PRSS50 | ||
Description by TissGene annotations |
* Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO term | PubMed ID | GO:0006508 | proteolysis | 17283160 | GO:0006508 | proteolysis | 17283160 |
Top |
TissGeneExp for PRSS50 |
Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
- Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
LUAD | -0.552026064 | -2.392188133 | 1.840162069 | 1.92E-08 | 8.28E-08 |
PRAD | -2.557181502 | -1.363258425 | -1.193923077 | 1.18E-05 | 6.37E-05 |
BRCA | -1.837113148 | -0.106260516 | -1.730852632 | 2.40E-15 | 1.27E-14 |
LUSC | -1.102077957 | -2.347317173 | 1.245239216 | 0.000344 | 0.000677767 |
Top |
TissGene-miRNA for PRSS50 |
Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
Top |
TissGeneMut for PRSS50 |
TissGeneSNV for PRSS50 |
nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
- nsSNVs sorted by frequency. |
AAchange | Cancer type | # samples |
p.D206N | SKCM | 2 |
p.R10C | PAAD | 1 |
p.T230M | PRAD | 1 |
p.K235N | LIHC | 1 |
p.P44L | PRAD | 1 |
p.R102H | READ | 1 |
p.E118K | BLCA | 1 |
p.C296Y | STAD | 1 |
p.K211E | UCEC | 1 |
p.A119V | SKCM | 1 |
p.A339V | PRAD | 1 |
p.S107F | SKCM | 1 |
p.A22T | COAD | 1 |
p.E319K | SKCM | 1 |
p.S337I | KIRC | 1 |
p.P77L | COAD | 1 |
p.P66L | SKCM | 1 |
p.W254* | KIRC | 1 |
p.A40T | BRCA | 1 |
p.Q350* | SKCM | 1 |
p.E262K | SKCM | 1 |
p.P112S | SKCM | 1 |
p.R71H | UCEC | 1 |
p.P100Q | LUAD | 1 |
p.S219I | UCEC | 1 |
p.D54N | UCEC | 1 |
p.P44L | LGG | 1 |
p.R10C | UCEC | 1 |
p.S145F | PRAD | 1 |
p.D231N | SKCM | 1 |
p.V8I | ACC | 1 |
p.Q350X | SKCM | 1 |
p.P284S | STAD | 1 |
p.F91L | UCEC | 1 |
p.M318I | SKCM | 1 |
p.E338K | BLCA | 1 |
p.W254X | KIRC | 1 |
Top |
TissGeneCNV for PRSS50 |
Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
Top |
TissGeneFusions for PRSS50 |
Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
TCGAfusionPortal | PRADA | LUSC | TCGA-22-4601-01A | INADL-PRSS50 | In-frame | Chr1:62393501 | Chr3:46761493 |
Top |
TissGeneNet for PRSS50 |
Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
Top |
TissGeneProg for PRSS50 |
Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Top |
TissGeneClin for PRSS50 |
TissGeneDrug for PRSS50 |
Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
TissGeneDisease for PRSS50 |
Disease information associated with TissGene (DisGeNet, 2016-06-01) |
Disease ID | Disease name | # pubmeds | Source |
umls:C0006142 | Malignant neoplasm of breast | 6 | BeFree |
umls:C0678222 | Breast Carcinoma | 6 | BeFree |
umls:C0596263 | Carcinogenesis | 3 | BeFree |
umls:C0007847 | Malignant tumor of cervix | 1 | BeFree |
umls:C0007873 | Uterine Cervical Neoplasm | 1 | BeFree |
umls:C0009402 | Colorectal Carcinoma | 1 | BeFree |
umls:C0027627 | Neoplasm Metastasis | 1 | BeFree |
umls:C0027658 | Neoplasms, Germ Cell and Embryonal | 1 | LHGDN |
umls:C0153676 | Secondary malignant neoplasm of lung | 1 | BeFree |
umls:C0302592 | Cervix carcinoma | 1 | BeFree |
umls:C0346429 | Multiple malignancy | 1 | BeFree |
umls:C1302401 | Adenoma of large intestine | 1 | BeFree |
umls:C1458155 | Mammary Neoplasms | 1 | BeFree,LHGDN |
umls:C1516170 | Cancer Cell Growth | 1 | BeFree |